Although gastrointestinal stromal tumours (GISTs) are genetically heterogeneous, the identification of receptor tyrosine kinase mutations has led to improved treatments using targeted therapy. This Review discusses how the underlying genetics influences GIST disease progression and therapeutic responses, new insights into the cellular origins of GISTs and strategies for overcoming therapeutic resistance.
- Christopher L. Corless
- Christine M. Barnett
- Michael C. Heinrich